3 research outputs found
Vitamin D, cellular senescence and chronic kidney diseases: what is missing in the equation?
As life expectancy increases in many countries, the prevalence of age-related diseases also
rises. Among these conditions, chronic kidney disease is predicted to become the second cause of
death in some countries before the end of the century. An important problem with kidney diseases is
the lack of biomarkers to detect early damage or to predict the progression to renal failure. In addition,
current treatments only retard kidney disease progression, and better tools are needed. Preclinical
research has shown the involvement of the activation of cellular senescence-related mechanisms
in natural aging and kidney injury. Intensive research is searching for novel treatments for kidney
diseases as well as for anti-aging therapies. In this sense, many experimental shreds of evidence
support that treatment with vitamin D or its analogs can exert pleiotropic protective effects in kidney
injury. Moreover, vitamin D deficiency has been described in patients with kidney diseases. Here, we
review recent evidence about the relationship between vitamin D and kidney diseases, explaining the
underlying mechanisms of the effect of vitamin D actions, with particular attention to the modulation
of cellular senescence mechanismsThis research was funded by grants from the Instituto de Salud Carlos III (ISCIII) and
Fondos FEDER European Union (PI20/00140, PI19/00240, PI19/00815, and DTS20/00083). Red de
Investigación Renal REDINREN: RD16/0009/0003 to M.R.-O. and RICORS2040; RD21/0005/0002
funded by European Union—NextGenerationEU, INNOREN cm (P2022/BMD-7221) of the Comunidad de Madrid, Sociedad Española de Nefrología. Innovation programme under the Marie
Skłodowska-Curie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699) to M.R.-
CCN2 Binds to Tubular Epithelial Cells in the Kidney
Cellular communication network-2 (CCN2), also called connective tissue growth factor (CTGF), is considered a fibrotic biomarker and has been suggested as a potential therapeutic target for kidney pathologies. CCN2 is a matricellular protein with four distinct structural modules that can exert a dual function as a matricellular protein and as a growth factor. Previous experiments using surface plasmon resonance and cultured renal cells have demonstrated that the C-terminal module of CCN2 (CCN2(IV)) interacts with the epidermal growth factor receptor (EGFR). Moreover, CCN2(IV) activates proinflammatory and profibrotic responses in the mouse kidney. The aim of this paper was to locate the in vivo cellular CCN2/EGFR binding sites in the kidney. To this aim, the C-terminal module CCN2(IV) was labeled with a fluorophore (Cy5), and two different administration routes were employed. Both intraperitoneal and direct intra-renal injection of Cy5-CCN2(IV) in mice demonstrated that CCN2(IV) preferentially binds to the tubular epithelial cells, while no signal was detected in glomeruli. Moreover, co-localization of Cy5-CCN2(IV) binding and activated EGFR was found in tubules. In cultured tubular epithelial cells, live-cell confocal microscopy experiments showed that EGFR gene silencing blocked Cy5-CCN2(IV) binding to tubuloepithelial cells. These data clearly show the existence of CCN2/EGFR binding sites in the kidney, mainly in tubular epithelial cells. In conclusion, these studies show that circulating CCN2(IV) can directly bind and activate tubular cells, supporting the role of CCN2 as a growth factor involved in kidney damage progression
CCN2 Increases TGF-β Receptor Type II Expression in Vascular Smooth Muscle Cells: Essential Role of CCN2 in the TGF-β Pathway Regulation
The cellular communication network factor 2 (CCN2/CTGF) has been traditionally described as a mediator of the fibrotic responses induced by other factors including the transforming growth factor β (TGF-β). However, several studies have defined a direct role of CCN2 acting as a growth factor inducing oxidative and proinflammatory responses. The presence of CCN2 and TGF-β together in the cellular context has been described as a requisite to induce a persistent fibrotic response, but the precise mechanisms implicated in this relation are not described yet. Considering the main role of TGF-β receptors (TβR) in the TGF-β pathway activation, our aim was to investigate the effects of CCN2 in the regulation of TβRI and TβRII levels in vascular smooth muscle cells (VSMCs). While no differences were observed in TβRI levels, an increase in TβRII expression at both gene and protein level were found 48 h after stimulation with the C-terminal fragment of CCN2 (CCN2(IV)). Cell pretreatment with a TβRI inhibitor did not modify TβRII increment induced by CCN2(VI), demonstrating a TGF-β-independent response. Secondly, CCN2(IV) rapidly activated the SMAD pathway in VSMCs, this being crucial in the upregulation of TβRII since the preincubation with an SMAD3 inhibitor prevented it. Similarly, pretreatment with the epidermal growth factor receptor (EGFR) inhibitor erlotinib abolished TβRII upregulation, indicating the participation of this receptor in the observed responses. Our findings suggest a direct role of CCN2 maintaining the TGF-β pathway activation by increasing TβRII expression in an EGFR-SMAD dependent manner activation